Cargando…

Quality of Life in Patients With Severe Skin Reactions in Course of First-Generation Epidermal Growth Factor Receptor Inhibitors Monoclonal Antibodies (Our Experience With Cetuximab)

BACKGROUND: Metastatic colorectal cancer (mCRC) with wild type expression of RAS and RAF genes can be treated with anti-epidermal growth factor receptor (EGFR) monoclonal antibodies, such as cetuximab, in combination with chemotherapy. Skin toxicity represents the most serious and frequent side effe...

Descripción completa

Detalles Bibliográficos
Autores principales:	De Luca, Rossella, Lo Coco, Gianluca, Addeo, Raffaele, Fattoruso, Silvia Ileana Sara, Auriemma, Annunziata, Paci, Roberta, Mistretta, Ornella, Epifanio, Maria Stella, Salvato, Angela, D’Agostino, Alberto, Cicero, Giuseppe
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Elmer Press 2021
Materias:	Original Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8297050/ https://www.ncbi.nlm.nih.gov/pubmed/34349854 http://dx.doi.org/10.14740/wjon1381

Ejemplares similares

Prognostic value of diabetes and metformin use in a real-life population of head and neck cancer patients
por: De Falco, Vincenzo, et al.
Publicado: (2023)

Chimeric Monoclonal Antibody Cetuximab Targeting Epidermal Growth Factor-Receptor in Advanced Non-Melanoma Skin Cancer
por: Wollina, Uwe, et al.
Publicado: (2017)

Clinical activity of regorafenib in elderly patients with recurrent glioblastoma
por: Fasano, Morena, et al.
Publicado: (2023)

The Art of Counseling in the Treatment of Head and Neck Cancer: Exploratory Investigation among Perceptions of Health Professionals in Southern Italy
por: Addeo, Raffaele, et al.
Publicado: (2022)

A case of Ménétriere´s disease treated with the monoclonal antibody cetuximab
por: Carlsen, Arne, et al.
Publicado: (2019)

Erratum to: Insulin-like growth factor 1 receptor mediated tyrosine 845 phosphorylation of epidermal growth factor receptor in the presence of monoclonal antibody cetuximab
por: Iyer, Gopal, et al.
Publicado: (2016)

The distribution of the therapeutic monoclonal antibodies cetuximab and trastuzumab within solid tumors
por: Lee, Carol M, et al.
Publicado: (2010)

Epidermal growth factor receptor double targeting by a tyrosine kinase inhibitor (Iressa) and a monoclonal antibody (Cetuximab). Impact on cell growth and molecular factors
por: Fischel, J-L, et al.
Publicado: (2005)

Antitumor efficacy of triple monoclonal antibody inhibition of epidermal growth factor receptor (EGFR) with MM151 in EGFR-dependent and in cetuximab-resistant human colorectal cancer cells
por: Napolitano, Stefania, et al.
Publicado: (2017)

TAS-102 in metastatic colorectal cancer (mCRC): efficacy, tolerability, and quality of life in heavily pretreated elderly patients: a real-life study
por: Cicero, Giuseppe, et al.
Publicado: (2020)

Epidermal growth factor receptor mutation mediates cross-resistance to panitumumab and cetuximab in gastrointestinal cancer
por: Braig, Friederike, et al.
Publicado: (2015)

Epidermal growth factor receptor (EGFR) gene promoter methylation and cetuximab treatment in colorectal cancer patients
por: Scartozzi, M, et al.
Publicado: (2011)

Phase I study of bortezomib and cetuximab in patients with solid tumours expressing epidermal growth factor receptor
por: Dudek, A Z, et al.
Publicado: (2009)

Incidence of cetuximab-related infusion reaction in head and neck cancer patients: may we predict it?
por: Merlano, Marco C, et al.
Publicado: (2018)

Monoclonal Antibodies to Treat Multiple Myeloma: A Dream Come True
por: D’Agostino, Mattia, et al.
Publicado: (2020)

EGFR Monoclonal Antibodies in the Treatment of Squamous Cell Carcinoma of the Head and Neck: A View beyond Cetuximab
por: Kono, Scott A., et al.
Publicado: (2012)

Characterization of 7A7, an anti-mouse EGFR monoclonal antibody proposed to be the mouse equivalent of cetuximab
por: He, Xuzhi, et al.
Publicado: (2018)

Tomotherapy concomitant with cetuximab, followed by cetuximab as single-agent therapy for unresectable squamous cell carcinoma of the skin: a case report
por: Falivene, Sara, et al.
Publicado: (2014)

Therapeutic antitumor efficacy of anti-epidermal growth factor receptor antibody, cetuximab, against malignant pleural mesothelioma
por: KURAI, JUN, et al.
Publicado: (2012)

Enhanced Antitumor Effects of Epidermal Growth Factor Receptor Targetable Cetuximab-Conjugated Polymeric Micelles for Photodynamic Therapy
por: Chang, Ming-Hsiang, et al.
Publicado: (2018)

Study and ICH validation of a reverse-phase liquid chromatographic method for the quantification of the intact monoclonal antibody cetuximab()
por: Martínez-Ortega, Antonio, et al.
Publicado: (2016)

Cetuximab Prevents Methotrexate-Induced Cytotoxicity in Vitro through Epidermal Growth Factor Dependent Regulation of Renal Drug Transporters
por: Caetano-Pinto, Pedro, et al.
Publicado: (2017)

Epidermal growth factor receptor gene copy number in 101 advanced colorectal cancer patients treated with chemotherapy plus cetuximab
por: Campanella, Carla, et al.
Publicado: (2010)

Epidermal Growth Factor Receptor Mutation Status and Rad51 Determine the Response of Glioblastoma to Multimodality Therapy with Cetuximab, Temozolomide, and Radiation
por: Wachsberger, Phyllis Rachelle, et al.
Publicado: (2013)

(111)In-cetuximab as a diagnostic agent by accessible epidermal growth factor (EGF) receptor targeting in human metastatic colorectal carcinoma
por: Shih, Ying-Hsia, et al.
Publicado: (2015)

Monoclonal Antibodies against Epidermal Growth Factor Receptor in Solid Tumors
por: Saba, Nabil F., et al.
Publicado: (2012)

Gene expression signatures modulated by epidermal growth factor receptor activation and their relationship to cetuximab resistance in head and neck squamous cell carcinoma
por: Fertig, Elana J, et al.
Publicado: (2012)

Expression of Epidermal Growth Factor Receptor Detected by Cetuximab Indicates Its Efficacy to Inhibit In Vitro and In Vivo Proliferation of Colorectal Cancer Cells
por: Shigeta, Kohei, et al.
Publicado: (2013)

Cetuximab in the management of colorectal cancer
por: Lenz, Heinz-Josef
Publicado: (2007)

Phase I Study of Ficlatuzumab and Cetuximab in Cetuximab-Resistant, Recurrent/Metastatic Head and Neck Cancer
por: Bauman, Julie E., et al.
Publicado: (2020)

One more piece to SOLIDify our knowledge on the impact of SARS-CoV-2 in patients with cancer
por: Addeo, Alfredo, et al.
Publicado: (2022)

Macrophage Migration Inhibitory Factor Is a Molecular Determinant of the Anti-EGFR Monoclonal Antibody Cetuximab Resistance in Human Colorectal Cancer Cells
por: Russo, Rosita, et al.
Publicado: (2019)

Anti-EGFR monoclonal antibody Cetuximab displays potential anti-cancer activities in feline oral squamous cell carcinoma cell lines
por: Altamura, Gennaro, et al.
Publicado: (2022)

Hugo Fattoruso songbook : instrumentals, canciones, parcerias.
por: Fattoruso, Hugo
Publicado: (2010)

Cetuximab and platinum-based chemoradio- or chemotherapy of patients with epidermal growth factor receptor expressing adenoid cystic carcinoma: a phase II trial
por: Hitre, E, et al.
Publicado: (2013)

Silibinin: A New Opportunity for the Treatment of Brain Metastasis from Lung Cancer
por: Addeo, Raffaele
Publicado: (2021)

Impact of cetuximab conventional dosing on cetuximab-induced magnesium concentration under haemodialysis in head and neck cancer
por: Thariat, Juliette, et al.
Publicado: (2008)

The Role of Monoclonal Antibodies in the First-Line Treatment of Transplant-Ineligible Patients with Newly Diagnosed Multiple Myeloma
por: Bonello, Francesca, et al.
Publicado: (2020)

Comparative Effectiveness and Safety of Monoclonal Antibodies (Bevacizumab, Cetuximab, and Panitumumab) in Combination with Chemotherapy for Metastatic Colorectal Cancer: A Systematic Review and Meta-Analysis
por: da Silva, Wânia Cristina, et al.
Publicado: (2018)

Is the sublay self-gripping mesh effective for incisional ventral hernia repair? Our experience and a systematic review of the literature
por: Schembari, Elena, et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_42nkul38tflv1kt9kmanrge341